No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
www.dcpc.comNo one on the platform currently holds 600062.SS.
No tracked institution reports a position in 600062.SS as of their last filing.
No one on the platform has traded 600062.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 15.0% | 16.8% | 15.7% | — | — | — |
| Rev. Growth % | -1.9% | 5.3% | ||||
| Profit Margin % | 15.0% | 13.4% | 12.8% | |||
| Free Cash Flow Margin % | 7.9% | 9.1% | 11.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $11.4B | -1.9% | $1.70 | $1.67–$1.73 | — | 2 |
| 2027 | $12.0B | +5.3% | $1.82 | $1.76–$1.88 | — | 2 |
| 2028 | $12.6B | +4.7% | $2.00 | $1.98–$2.02 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600062.SSChina Resources Double-Crane Pharmaceutical Co.,Ltd. | $15.94 | -0.25% | $16.6B | — |
| 000739.SZApeloa Pharmaceutical Co.,Ltd | $22.23 | -0.63% | $25.8B | — |
| 300142.SZWalvax Biotechnology Co., Ltd. | $12.93 | -0.61% | $20.7B | — |
| 300199.SZHybio Pharmaceutical Co., Ltd. | $23.38 | -0.89% | $20.7B | — |
| 300436.SZFujian Cosunter Pharmaceutical Co., Ltd. |
| $84.45 |
| -0.51% |
| $13.5B |
| — |
| 300601.SZShenzhen Kangtai Biological Products Co., Ltd. | $11.56 | -0.86% | $12.9B | — |
| 600380.SSJoincare Pharmaceutical Group Industry Co.,Ltd. | $9.23 | +0.00% | $16.9B | — |
Source: Financial Modeling Prep · peers by sector/industry